Abpro Announces Closing of Business Combination With Atlantic Coastal Acquisition Corp. II
Abpro Announces Closing of Business Combination With Atlantic Coastal Acquisition Corp. II
- Abpro Expected to Begin Trading on Nasdaq on Wednesday, November 13, 2024 Under the Tickers "ABP" and "ABPWW"
- Abpro預計將於2024年11月13日星期三在納斯達克開始交易，股票代碼爲"ABP"和"ABPWW"
WOBURN, Mass. and NEW YORK, Nov. 13, 2024 /PRNewswire/ -- Abpro Corporation, a biotechnology company with the mission of improving the lives of those facing severe and life-threatening diseases with next-generation antibody therapies, and Atlantic Coastal Acquisition Corp. II, a special purpose acquisition company ("Atlantic Coastal"), today announced the completion of the closing of their previously announced business combination, which was approved by Atlantic Coastal's stockholders on November 7, 2024. The combined company will operate as Abpro Holdings, Inc. ("Abpro Holdings") with Abpro Corporation as a wholly-owned subsidiary of Abpro Holdings (collectively, "Abpro"). Abpro Holdings' common stock is expected to begin trading on The Nasdaq Global Market under the ticker symbol "ABP" and its warrants are expected to begin trading on The Nasdaq Capital Market under the ticker symbol "ABPWW" on Thursday, November 14, 2024.
馬薩諸塞州沃本和紐約市，2024年11月13日 /PRNewswire/ -- Abpro公司是一家生物技術公司，致力於通過新一代抗體治療改善面臨嚴重和危及生命疾病的患者生活，亞特蘭大沿海收購公司II（"亞特蘭大沿海"）今天宣佈完成其先前宣佈的業務合併，合併獲得亞特蘭大沿海股東於2024年11月7日的批准。合併後的公司將作爲Abpro Holdings, Inc.（"Abpro Holdings"）運營，Abpro公司將作爲Abpro Holdings的全資子公司（統稱爲"Abpro"）。Abpro Holdings的普通股預計將在納斯達克全球市場下以股票代碼"ABP"開始交易，其warrants預計將在納斯達克資本市場下以股票代碼"ABPWW"開始交易，時間爲2024年11月14日星期四。
Abpro is currently in the developmental phase of its next-generation antibody therapies, focusing on HER2+ cancer treatments, including breast, gastric and colorectal cancers, in addition to treatments for Wet AMD/DME and COVID-19. These antibodies are developed using Abpro's proprietary DiversImmune platform. Abpro has partnered with Celltrion, which is a leading South Korean pharmaceutical company, in an exclusive collaboration to further advance ABP 102, a t-cell engager, which is being developed for the treatment of HER2+ breast, gastric and pancreatic cancer. In connection with the business combination, Celltrion purchased $5,000,000 of Abpro common stock in a PIPE transaction, and Soo Young Lee of Celltrion joined Abpro's board of directors.
Abpro目前處於其新一代抗體療法的開發階段，重點針對HER2+癌症治療，包括乳腺癌、胃癌和結直腸癌，以及溼性年齡相關性黃斑變性/糖尿病性黃斑水腫和COVID-19的治療。這些抗體是使用Abpro專有的DiversImmune平台開發的。Abpro與韓國領先的藥品公司Celltrion建立了獨家合作關係，以進一步推進用於HER2+乳腺癌、胃癌和胰腺癌治療的t細胞連接物ABP 102。在業務合併過程中，Celltrion以PIPE交易購買了價值5,000,000美元的Abpro普通股，Celltrion的Soo Young Lee加入了Abpro的董事會。
Brookline Capital Markets, a Division of Arcadia Securities, LLC, acted as a financial advisor to Abpro Corporation and placement agent to Atlantic Coastal. Pillsbury Winthrop Shaw Pittman LLP acted as legal counsel to Atlantic Coastal, and Nelson Mullins Riley & Scarborough LLP acted as legal counsel to Abpro.
Brookline Capital Markets，是Arcadia Securities, LLC的一個部門，充當Abpro公司的財務顧問以及亞特蘭大沿海的配售代理。Pillsbury Winthrop Shaw Pittman LLP擔任亞特蘭大沿海的法律顧問，而Nelson Mullins Riley & Scarborough LLP擔任Abpro的法律顧問。
About Abpro
關於Abpro
Abpro is a biotechnology company located in Woburn, Massachusetts. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. For more information, please visit .
Abpro是一家位於馬薩諸塞州沃本的生物技術公司。公司的使命是通過下一代抗體療法改善人類面對嚴重和危及生命疾病的生活。欲了解更多信息，請訪問 .
SOURCE Abpro
來源 Abpro
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎？
譯文內容由第三人軟體翻譯。
